Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study.

Cancer Immunol Immunother · 2026 · PMC12847551 · PMID 41591537

Europe PMC DOI

hedged sentences

0.0849

closest p · 1.7× alpha

0.2080

boldest claim

The sentences

marginally significantP = 0.0849so close (0.05 < p ≤ 0.1)

A marginally significant difference in OS was observed between the two groups ( P = 0.0849), as shown in Fig. 4 .

also in 26,082 other papers

did not reach statistical significanceP = 0.208not close (p > 0.1)

Comparisons of PFS across all three groups did not reach statistical significance ( P = 0.208).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.